Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 08, 2006. The report details a specific corporate action regarding share repurchases authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 670,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,496.5184 pence per share.
- Transaction Date: June 08, 2006.
Material Changes
Following the repurchase, the Company's share capital structure changed as follows:
- Treasury Shares: The Company now holds 170,871,678 shares in Treasury.
- Shares in Issue: There are 5,811,560,025 shares in issue (excluding Treasury shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies beyond the specific transaction details. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the 670,000 shares purchased at 1,496.5184 pence per share.
- Confirm the updated total number of shares in issue (5,811,560,025) against subsequent filings.
- Review the remaining authorization for share buybacks under the mandate granted on May 17, 2006.